China Resources Sanjiu Medical & Pharmaceutical Co Ltd (CR Sanjiu), a subsidiary of China Resources Pharmaceutical Group Ltd, discovers, develops, manufactures, and distributes pharmaceutical products and other health products and services. The company's product portfolio includes pharmaceuticals such as over-the-counter (OTC) drugs, and Active pharmaceutical ingredients (APIs), Chinese prescription medicines, and traditional Chinese medicine (TCM) formula granules. CR Sanjiu's product consumer products covering categories such as colds, gastrointestinal, dermatology, hepatobiliary, pediatrics, orthopedics, and gynecology. Its prescription drug products address therapeutic areas like cardiovascular and metabolic diseases, oncology, respiratory diseases, neurological/psychiatric diseases, digestive diseases, orthopedics, and anti-infectives. Its key products include Compound Danshen Dripping Pills, Xue Sai Tong Sanqi series, Yangxue Qingnao Granules, Shenfu Injection, and Huachansu Tablets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CR Sanjiu's R&D arm focuses on innovation-driven development by increasing R&D investment and strengthening innovation pipelines and technology platforms. The company focuses on differentiated positioning in CHC, prescription drugs, Panax notoginseng products, and traditional Chinese medicines. It aims to build a diversified product matrix in self-treatment and a multi-tiered R&D pipeline in prescription drugs. The company has established a systematic R&D system with "six institutes and three laboratories" to capture strategic development opportunities and enhance innovation potential. It also focuses on strengthening its talent pool and establishing industry-university-research cooperation bases. The company has set up national and provincial-level innovation platforms to tackle key technologies and integrate industry resources. The R&D units of CR Sanjiu include the Health Drug Research Institute, Innovative Drug Research Institute, Traditional Chinese Medicine Research Institute, Traditional Chinese Medicine Resources Research Institute, Advanced Delivery Research Institute, Process Technology Research Institute, Deep Blue Laboratory, Fuxi Laboratory, and Waterdrop Laboratory. These units are responsible for managing the company's R&D activities by capturing strategic development opportunities and tapping into innovation potential. In FY2025, the company spent CNY1,733.5 million on R&D, which, as a percentage of revenue, stood at 5.5% and grew 81.1% YoY.